



## Curriculum Vitae

Personal information Sarah Zohar

### Work experience

---

- Jan 2025- Current Director of Research (DR) at the French National Institute of Health and Medical Research (Inserm) located at ParisSanté Cumpus leader of UMR 1346 HeKA “Digital health research for a learning health system”, affiliated to Inserm, Inria, Université Paris Cité, Paris, France.
- Nov 2018 – Nov 2024 French authority evaluating Health Products and Technologies (Haute Autorité de Santé (HAS)), Voting substitutes member of the "Medical Device and Health Technology Evaluation Committee" (CNEDiMTS).
- Dec 2015- Dec 2024 Director of Research (DR) at the French National Institute of Health and Medical Research (Inserm) located at ParisSanté Cumpus leader of team HeKA “Digital health research for a learning health system”, affiliated to Inserm, Inria, Université Paris Cité, Paris, France.
- Dec 2015- Dec 2021 Director of Research (DR) at the French National Institute of Health and Medical Research (Inserm) located at Cordeliers Research Centre (UMRS 1138) deputy leader of team number 22, entitled: “Information science to support personalized medicine” (lead by Anita Burgun), Paris, France.
- Oct 2012-Nov 2015 Research associate (CR) at the French National Institute of Health and Medical Research (Inserm) located at Cordeliers Research Centre (U1138) team number 22, entitled: “Information science to support personalized medicine”, Paris, France.
- Oct 2009-Sept2012 Research associate (CR) at Inserm (U717) located at Saint-Louis university Hospital, department of “Biostatistics and Clinical Epidemiology”, Paris, France.
- July 2005-Sept 2009 Research statistician (IR) at Inserm, located at Saint-Louis research Hospital, department of “Clinical Research Centre” (CIC 9504), Clinical Research Centre of Saint-Louis hospital, Paris, France.
- Dec 2002-June 2005 Research statistician at Saint-Louis university Hospital, department of “Biostatistics and Clinical Computing”, Paris, France.

### Education and training

---

- 2011 Habilitation qualification to supervise scientific research, University Denis Diderot Paris 7, Paris, France
- 1999-2002 PhD in Biomathematics, University Denis Diderot Paris 7, Paris,

France. Title: "Bayesian statistics in clinical trials – Proposition of stopping rules for phase I or II therapeutic trials". PhD grant: Ministry of Research, France.  
1997-1999 Master Degree in Biomathematics, University Denis Diderot Paris 7, Paris, France

## Additional information

---

### Publications

<https://orcid.org/0000-0002-8429-2340>

More than 150 scientific publications.

### Projects

2024-2029 EU Horizon INVENTS "Innovative designs, extrapolation, simulation methods and evidence-tools for rare diseases addressing regulatory needs" (8.7 M€) **Project PI**

2023-2029 France 2030 ANR PEPR Digital Health - SMATCH "Statistical and AI based Methods for Advanced Clinical Trials CHallenges in Digital Health" (3M€) **Project co-PI** with R Thiebaut

2024-2029 EU MSCA Doctoral Networks -Project ORGESTRA "Organoid technologies for disease modeling, drug discovery and development for rare diseases". **WP leader** of methodological design for using organoids outcomes and transfer it to clinic.

2025-2030 EU IHI Realised "compRehensive mEthodological and operational Approach to cLinical trlals in ultra rarE Diseases". **Participant partner.**

2025-2030 EU Joint Transnational Call ERDERA "Rare Disease Research Alliance". **Participant partner.**

2025-2030 EU Joint Action eCAN+ "Strengthening eHealth for Cancer Prevention & Care". **Task leader** on the Creation of a taxonomy or classification of digital health technologies in the field of cancer.

2023 ANR AAP MRSEI - Montage de Réseaux Scientifiques Européens ou Internationaux - MRSEI 2023. (27k€) **Project PI**

2023-2025: Combo-"Evaluating new combinations in oncology with Real-World Data and state-of-the-art knowledge". Sanofi-HDH-CLB-Inria (500k€) (**team co-leader**).

2020-2025: European project FAIR EU H2020-SC1-2019-847786-2, "Flagellin aerosol therapy as an immunomodulatory adjunct to the antibiotic treatment of drug resistant bacterial pneumonia", **Workpackage co-leader** "Development of a translational modelling and simulation platform and Bayesian adaptive design for flagellin PK/PD" (873 000€, for the WP).

### Memberships

Journal associate Editor; (1) Biometrics and (2) Statistics for Biopharmaceutical Research

Biosketch:

Head of the research unit HeKA "Digital health research for a learning health system", affiliated to Inserm (French National Institute of Health and Medical Research), Inria (National Institute for Research in Digital Science and Technology) and Université Paris Cité. Sarah Zohar is an expert in innovative methods for interventional and observational health data modeling including drug and Digital Medical Devices evaluation. She has made many methodological contributions for exploratory clinical trials and Real World Data analysis proposing novel methods and approaches that have been applied in cancer, rare diseases, resistance to antibiotics and pediatric clinical trials among other fields. She has collaborated with physicians in the designing, planning, conducting and analyzing clinical trials and she has developed new approaches in collaboration with international methodological experts from USA, Japan and Europe.

She's coordinating the EU Horizon collaborative project INVENTS "Innovative designs, extrapolation, simulation methods and evidence-tools for rare diseases addressing regulatory needs" and co-leading the France 2030 PEPR Digital Health SMATCH "Statistical and AI based Methods for Advanced Clinical Trials CHallenges in Digital Health".

She was a voting member for 6 years (2018-2024) at the French HTA for Medical Device reimbursement commission, that is, CNEDIMTS at HAS ("Haute Autorité de Santé", BMJ Evidence Based Medicine 2023. (<http://dx.doi.org/10.1136/bmiebm-2022-112091>). She is part of the European taskforce of EIT Health and the French Ministry of Solidarity and Health for "harmonization of clinical studies criteria & methodologies in Europe for the evaluation of digital medical devices. She has been invited to speak as Key note speaker or contributor at a number of international scientific meetings.

Other Relevant Information